

Table 22: Clinical evidence profile: Comparison 1.2.1. Mannitol versus Dornase alfa

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Mannitol	Dornase alfa	Relative (95% CI)	Absolute		
FEV₁ (% change from baseline) - Up to 3 months (follow-up 3 months; range of scores: 0-100; Better indicated by higher values)												
1 (Mina sian 2010)	randomised trials ¹	serious ²	no serious inconsistency	serious ³	serious ⁴	none	20	-	-	MD 2.8 higher (4.8 lower to 10.4 higher)	VERY LOW	CRITICAL

Abbreviations: CI: confidence interval; FEV₁: forced expiratory volume in 1 second; MD: mean difference

1 Cross-over design

2 The quality of the evidence was downgraded by 1 because this is an open trial, and there is high risk of incomplete reporting

3 The quality of the evidence was downgraded by 1 as the participants in the trial underwent a tolerance test at screening. Those who fail were not entered in the study, and this limits the generalisability of the results to the general CF population

4 The quality of the evidence was downgraded by 1 as the 95% CI crossed 1 clinical MIDs